[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:alpha-1-antitrypsin-deficiency":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":116,"states":125},"Alpha-1 Antitrypsin Deficiency",17,14,[8,16,23,29,35,42,47,53,59,65,71,77,83,89,96,103,109],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05677971","Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein",[12],"Phase 3","RECRUITING","2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.809440Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07227207","A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:19:21.761002Z","2026-05-29T15:36:40.183026Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07555483","A Non-inferiority Pharmacokinetic and Safety\u002FTolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)",[12],"2026-08-26T02:17:16.980188Z","2026-05-13T02:55:06.722818Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06389877","A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)",[20],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.963180Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06996756","Gene Therapy for Alpha 1- Antitrypsin Deficiency",[39],"Phase 1","2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.296889Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":27,"content_modified":46},"NCT06165341","Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)",[12],"2026-05-05T02:43:27.102194Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06049082","A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency",[39],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:26.947574Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06512454","A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems",[],"2026-08-26T02:18:26.129155Z","2026-07-30T01:46:14.465963Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT04157049","Alpha-1 Research Registry",[],"2026-08-26T02:15:41.377360Z","2026-05-13T02:55:06.240996Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT01851642","Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs",[],"2026-08-26T02:18:24.494016Z","2026-05-13T02:55:06.078727Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT00500123","The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study",[],"2026-08-26T02:17:46.653867Z","2026-05-13T02:55:06.036872Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT06505603","PiMZ Longitudinal Cohort (PiMZ Logic)",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.497860Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT00001532","Role of Genetic Factors in the Development of Lung Disease",[],"2026-08-26T02:18:11.042248Z","2026-05-13T02:55:06.028695Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":94,"content_modified":95},"NCT07135427","Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency",[93],"Phase 4","2026-08-26T02:16:15.345907Z","2026-05-05T02:43:27.284358Z",{"nct_id":97,"title":98,"phases":99,"status":100,"updated_at":101,"content_modified":102},"NCT02796937","Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:15:46.655893Z","2026-06-16T05:54:07.954283Z",{"nct_id":104,"title":105,"phases":106,"status":100,"updated_at":107,"content_modified":108},"NCT00884455","Alpha-1 Foundation DNA and Tissue Bank",[],"2026-08-26T02:16:06.684983Z","2026-06-16T05:54:07.942982Z",{"nct_id":110,"title":111,"phases":112,"status":113,"updated_at":114,"content_modified":115},"NCT06738017","Study of BMN 349 Single Dose in PiZZ and PiMZ\u002FMASH Adult Participants",[39],"ACTIVE_NOT_RECRUITING","2026-08-03T02:27:16.454962Z","2026-05-05T02:43:27.830799Z",[117,121],{"biomarker":118,"count":119,"slug":120},"SERPINA1 Gene",4,"serpina1-gene",{"biomarker":122,"count":123,"slug":124},"Aspartate Aminotransferase",3,"aspartate-aminotransferase",[126,130,134,138,141,144,147,150,153,156,159],{"state":127,"count":128,"slug":129},"Florida",10,"florida",{"state":131,"count":132,"slug":133},"South Carolina",8,"south-carolina",{"state":135,"count":136,"slug":137},"Alabama",5,"alabama",{"state":139,"count":136,"slug":140},"California","california",{"state":142,"count":136,"slug":143},"Texas","texas",{"state":145,"count":119,"slug":146},"Arizona","arizona",{"state":148,"count":119,"slug":149},"Massachusetts","massachusetts",{"state":151,"count":119,"slug":152},"New York","new-york",{"state":154,"count":119,"slug":155},"Ohio","ohio",{"state":157,"count":123,"slug":158},"Colorado","colorado",{"state":160,"count":123,"slug":161},"Minnesota","minnesota"]